This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Calvo X, Florensa L, Arenillas L . Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes? Leukemia 2017; e-pub ahead of print 18 August 2017; doi:10.1038/leu.2017.237.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Abou Zahr A, Kavi AM, Mukherjee S, Zeidan AM . Therapy-related myelodysplastic syndromes, or are they? Blood Rev 2017; 31: 119–128.
Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197–205.
Brunning RD, Orazi A, Germing U, Le Beau MM, Porwitt A, Baumann J et alMyelodysplastic syndromes. In: Swerdlow S, Campos E, Lee Harris N et al (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, World Health Organization: Lyon, France, 2008, pp 87–107.
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017; 31: 1391–1397.
Quintas-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; 14: 401–410.
Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014; 28: 185–189.
Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96: 1433–1440.
Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113: 1351–1361.
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 2015; 33: 340–348.
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD et al. Myelodysplastic syndromes and acute myeloid leukemia after radiotherapy for prostate cancer: a population-based study. Prostate 2017; 77: 437–445.
Nazha A, Sekeres MA, Gore SD, Zeidan AM . Molecular testing in myelodysplastic syndromes for the practicing oncologist: will the progress fulfill the promise? Oncologist 2015; 20: 1069–1076.
Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 2017; 129: 2347–2358.
Acknowledgements
Funding for this research has been provided, in part, from the Edward P. Evans Foundation to MAS, DPS, JB and RK.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zeidan, A., Sekeres, M., Barnard, J. et al. Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?. Leukemia 31, 2539–2541 (2017). https://doi.org/10.1038/leu.2017.238
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.238